Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Neumora Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Neumora Therapeutics, Inc.

NMRA

Neumora Therapeutics, Inc.

About Neumora Therapeutics, Inc.

Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for brain diseases. Its pipeline includes programs targeting neuropsychiatric and neurodegenerative disorders, such as depression, dementia-related agitation, schizophrenia, ALS, and Parkinson’s disease. The company leverages novel mechanisms, AI-driven precision neuroscience, and proprietary compounds to address unmet medical needs in mental health and neurodegeneration.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Neumora Therapeutics, Inc.

1
1
Neumora Therapeutics, Inc. Neumora Therapeutics Reports $53.5 Million Net Loss in Q1 2026, Decreases Operating Expenses

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Neumora Therapeutics, Inc. Neumora Therapeutics Reports $236.9 Million Net Loss for 2025, Plans Key Program Updates in 2026

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Neumora Therapeutics, Inc. Neumora Therapeutics Reports $56.8 Million Net Loss in Q3 2025, Decreasing from Previous Year

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Neumora Therapeutics, Inc. Neumora Therapeutics Reports $120.7 Million Net Loss for First Half of 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Neumora Therapeutics, Inc. Neumora Therapeutics Reports $67.99 Million Net Loss in Q1 2025, Seeks Additional Capital

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Neumora Therapeutics, Inc. Neumora Therapeutics Reports $243.8 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Neumora Therapeutics, Inc. Neumora Therapeutics Reports Financial Results, Anticipates Additional Funding for Ongoing Operations and Product Development

Via official filing (AI summary) | over 1 year ago | 0 comments